Highlights of news on TP Therapeutics, Inc.

OncLive report on Repotrectinib: “Repotrectinib Shows Promising Activity in ROS1+ NSCLC”

Press release: “TP Therapeutics Announces Updated Interim Phase 1/2 Clinical Trial Data of Repotrectinib (TPX-0005) in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer Patients at 19th World Conference on Lung Cancer”

Press release: “TP Therapeutics Announces Updated Interim Phase 1 Data with Repotrectinib (TPX-0005) in ROS1 Fusion-positive NSCLC to be Presented at World Conference on Lung Cancer”

Press release: “Cancer Discovery Highlights Potent Effects of TP Therapeutics’ Novel, Lead Investigational Compound Repotrectinib in Tumors Harboring ROS1, TRK or ALK Fusions with Solvent Front Mutations”

Press release: “TP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TPX-0005 at ASCO 2018: Data Presented from the Ongoing TRIDENT-1 Study”

Press release: “TP Therapeutics Announces Phase 1 Data of TPX-0005 to be Presented at the Annual American Society of Clinical Oncology Meeting”

Press release: “TP Therapeutics Appoints Athena Countouriotis, M.D., as EVP and Chief Medical Officer”

Press release: “TP Therapeutics Appoints Lewis Shuster to Board of Directors”

Press release: “TP Therapeutics Appoints Sheila K. Gujrathi, MD to Board of Directors and as a Strategic Advisor”

Press release: “TP Therapeutics Announces FDA Orphan Drug Designation Granted to TPX-0005 for Treatment of Non-Small Cell Lung Adenocarcinomas Harboring ALK, ROS1, or NTRK Oncogenic Rearrangements”

FierceBiotech “Cancer Resistance Firm Reaps $45M in Third Round”

Press release: “TP Therapeutics Closes $45M Series C Financing”

San Diego Business Journal “TP Therapeutics Raises Nearly $18 Million in Series B Financing Round”